(CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression free survival (PFS) of 23.1 ...
(CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade - 3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression free ...
When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results